01301nas a2200433   4500000000100000000000100001008004100002653004400043653000900087653002200096653004200118653002800160653002400188653002500212653001100237653001100248653000900259653001600268653004300284653008000327653002600407653005900433653003700492653001300529653001800542653002100560653002400581100001600605700001500621700001300636700001500649700001300664700001500677245010800692250001500800300001400815490000700829020003100836       2021                            d10aAdrenal Cortex Hormones/therapeutic use10aAged10aAged, 80 and over10aBronchodilator Agents/adverse effects10aDelivery of Health Care10aDisease Progression10aEngland/epidemiology10aFemale10aHumans10aMale10aMiddle Aged10aMuscarinic Antagonists/adverse effects10a*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology10aRetrospective Studies10aGlobal Initiative for Chronic Obstructive Lung Disease10achronic obstructive lung disease10aDatabase10aexacerbations10ahealthcare costs10aMaintenance therapy1 aL. Sansbury1 aK. Rothnie1 aC. Bains1 aC. Compton1 aG. Anley1 aA. Ismaila00aHealthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England  a2021/09/24  a2591-26040 v16  a1176-9106 (Print)1176-9106